Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;330:205-206 (29 January), doi:10.1136/bmj.330.7485.205
Screening and increased use of adjuvants are responsibleadjuvants more so
| The first 150 words of the full text of this article appear below. |
The survival of women who will be diagnosed with breast cancer in the United Kingdom and Europe in 2005 is significantly better than that for their counterparts diagnosed in the 1970s and '80s, although five year survival remains lower in Europe than in the United States (79% v 89%).1 What is known about the reasons for these differences, and what could increase survival still more?
Any improvement in survival is unlikely to be attributable to a change in the biological behaviour of breast cancer. It must reflect improvement, therefore, in diagnosing and managing breast cancer, leading to fewer distant relapses and deaths. This could be a consequence of early detection through screening or improved systemic treatment with adjuvants after surgery to eliminate micrometastases and prevent recurrence. However, screening amounts to secondary prevention rather than primary prevention. Delay in diagnosing symptomatic breast cancer is associated with inferior survival,2 but as
Alison L Jones, consultant
Academic Department of Oncology, Royal Free and University College Hospitals, London NW3 2QG (alison.jones@royalfree.nhs.uk)
Read all Rapid Responses